Trial Profile
A Single Arm Clinical Evaluation of Safety and Efficacy of the Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Medtronic
- 12 Oct 2021 Planned End Date changed from 24 Dec 2024 to 2 Oct 2025.
- 22 Oct 2020 Planned End Date changed from 30 Sep 2024 to 24 Dec 2024.
- 22 Oct 2020 Planned primary completion date changed from 30 Sep 2020 to 31 Mar 2021.